Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ear, nose and throat (ENT) and allergy treatments, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management team will deliver a company overview and business update on December 5, 2024, at 1:30 p.m. ET. The presentation will be accessible via webcast on the Investors page of the Optinose website, with replay availability for 30 days after the event.
Optinose (NASDAQ:OPTN), un'azienda farmaceutica specializzata in trattamenti per orecchie, naso e gola (ENT) e allergie, ha annunciato la sua partecipazione alla 36ª Conferenza Sanitaria Annuale di Piper Sandler. Il team di gestione dell'azienda presenterà una panoramica dell'azienda e un aggiornamento commerciale il 5 dicembre 2024, alle 13:30 ET. La presentazione sarà disponibile in streaming sulla pagina Investitori del sito web di Optinose, con possibilità di riproduzione per 30 giorni dopo l'evento.
Optinose (NASDAQ:OPTN), una compañía farmacéutica especializada en tratamientos para oídos, nariz y garganta (ENT) y alergias, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El equipo de gestión de la compañía presentará una visión general de la empresa y una actualización comercial el 5 de diciembre de 2024, a la 1:30 p.m. ET. La presentación estará disponible a través de una transmisión en vivo en la página de Inversores del sitio web de Optinose, con disponibilidad de repetición durante 30 días después del evento.
Optinose (NASDAQ:OPTN), 귀, 코 및 인후(ENT) 및 알레르기 치료에 전문화된 제약 회사가 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진은 2024년 12월 5일 오후 1시 30분 ET에 회사 개요 및 비즈니스 업데이트를 제공할 예정입니다. 발표는 Optinose 웹사이트의 투자자 페이지를 통해 웹캐스트로 접근할 수 있으며, 행사 후 30일 동안 재생 가능성도 있습니다.
Optinose (NASDAQ:OPTN), une entreprise pharmaceutique spécialisée dans les traitements des oreilles, du nez et de la gorge (ENT) ainsi que des allergies, a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. L'équipe de direction de l'entreprise présentera un aperçu de la société et une mise à jour commerciale le 5 décembre 2024 à 13h30 ET. La présentation sera accessible par webdiffusion sur la page Investisseurs du site internet d'Optinose, avec une disponibilité de rediffusion pendant 30 jours après l'événement.
Optinose (NASDAQ:OPTN), ein Pharmaunternehmen, das sich auf Behandlungen für Ohren, Nase und Hals (ENT) sowie Allergien spezialisiert hat, hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler angekündigt. Das Management-Team des Unternehmens wird am 5. Dezember 2024 um 13:30 Uhr ET einen Unternehmensüberblick und eine Geschäftsupdate präsentieren. Die Präsentation wird über einen Webcast auf der Investorenseite der Optinose-Website verfügbar sein, mit einer Replay-Möglichkeit für 30 Tage nach der Veranstaltung.
- None.
- None.
YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 1:30 p.m. ET.
To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.
A replay of the webcast will be available for 30 days following the conclusion of the event.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
FAQ
When is Optinose (OPTN) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Optinose's (OPTN) presentation at the Piper Sandler Conference?
What will Optinose (OPTN) discuss at the Piper Sandler Healthcare Conference 2024?
What is Optinose's (OPTN) medical specialty focus?
